Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 5/20 | 0.78 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL21638965 | 1.00 | CA4 (0.78) | CA4FAHD1MEN1LDHABLM | |
| Oxalic Acid SCHEMBL8030480 | 0.94 | CA4 (0.70) | CA4FAHD1MEN1LDHABLM | |
| Oxalic Acid SCHEMBL863490 | 0.94 | CA4 (0.70) | CA4FAHD1MEN1LDHABLM | |
| Oxalic Acid SCHEMBL9879794 | 0.94 | CA4 (0.88) | CA4FAHD1MEN1LDHABLM | |
| Oxalic Acid SCHEMBL6018199 | 0.94 | CA4 (0.88) | CA4FAHD1MEN1LDHABLM | |
| Oxalic Acid SCHEMBL50017 | 0.94 | — | — | |
| Oxalic Acid SCHEMBL23706325 | 0.88 | — | — | |
| Oxalic Acid SCHEMBL3881271 | 0.88 | CA4 (0.78) | CA4FAHD1MEN1LDHABLM | |
| Oxalic Acid SCHEMBL20543321 | 0.88 | — | — | |
| Oxalic Acid SCHEMBL21951275 | 0.88 | CA4 (0.78) | CA4FAHD1MEN1LDHABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122071805-A | Ru-based alloy catalyst loaded by carbon carrier and application thereof | 天津科技大学 | 2026-05-22 | — | — | CN | claimed |
| EP-4661675-A1 | PARTICULATE MATERIAL COMPRISING SILVER PARTICLES WHICH ARE EQUIPPED WITH RUTHENIUM OXIDE AND ARE OPTIONALLY PARTIALLY OXIDIZED | Heraeus Precious Metals GmbH & Co. KG (DE) | 2025-12-17 | — | — | EP | claimed |
| EP-4624043-A1 | HYDROGENATION CATALYST | Hanwha Solutions Corporation (KR) | 2025-10-01 | — | — | EP | claimed |
| US-20250214864-A1 | PARTICULATE INORGANIC MATERIAL EQUIPPED WITH ELEMENTAL SILVER AND ELEMENTAL RUTHENIUM | HERAEUS PRECIOUS METALS GMBH & CO. KG (DE) | 2025-07-03 | — | — | US | claimed |
| US-20250177959-A1 | PARTICULATE CARBON MATERIAL PROVIDED WITH ELEMENTAL SILVER AND ELEMENTAL RUTHENIUM | HERAEUS PRECIOUS METALS GMBH & CO. KG (DE) | 2025-06-05 | — | — | US | claimed |
| CN-120091878-A | Unsupported bimetallic particulate material | 贺利氏贵金属有限两合公司 | 2025-06-03 | — | — | CN | claimed |
| CN-119776880-A | Controllable regulation MoO2Electrocatalyst with crystallinity, preparation method and application thereof | 佛山仙湖实验室 | 2025-04-08 | — | — | CN | claimed |
| EP-4527980-A2 | PARTICULATE INORGANIC MATERIAL PROVIDED WITH ELEMENTAL SILVER AND ELEMENTAL RUTHENIUM | Heraeus Precious Metals GmbH & Co. KG (DE) | 2025-03-26 | — | — | EP | claimed |
| CN-119663363-A | Rare earth element ruthenium-based composite catalyst and preparation method and application thereof | 厦门稀土材料研究所 | 2025-03-21 | — | — | CN | claimed |
| CN-119461519-A | Preparation method of ruthenium nitrosylnitrate | 云南贵金属实验室有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-110706938-A | Preparation method of supercapacitor electrode material | 中国科学院上海硅酸盐研究所 | 2020-01-17 | — | — | CN | claimed |
| US-7648977-B2 | Inhibits HIV-1(BaL) replication in Hut/CCR5 cells, HIV-1(IIIB) replication in GHOST/CXCR4 and normal human peripheral blood mononuclear cells (PBMC), and HIV-1 RT; antiviral agents; HIV | THE UNIVERSITY OF HONG KONG (HK) | 2010-01-19 | — | — | US | claimed |
| EP-1940385-A1 | PHARMACEUTICAL COMPOSITION HAVING A RUTHENIUM OXALATO COMPOUND AND METHOD OF USING THE SAME | The University of Hong Kong (CN) | 2008-07-09 | — | — | EP | claimed |
| US-20070105952-A1 | Pharmaceutical composition having a ruthenium oxalato compound and method of using the same | THE UNIVERSITY OF HONG KONG | 2007-05-10 | — | — | US | claimed |
| WO-2007048311-A1 | PHARMACEUTICAL COMPOSITION HAVING A RUTHENIUM OXALATO COMPOUND AND METHOD OF USING THE SAME | THE UNIVERSITY OF HONG KONG (CN) | 2007-05-03 | — | — | WO | claimed |
| CN-1033700-C | Method of producing straight-chain acrylonitrile dimers | UBE INDUSTRIES (JP) | 1997-01-01 | — | — | CN | claimed |
| EP-0559168-B1 | Method of producing straight-chain acrylonitrile dimers | UBE INDUSTRIES (JP) | 1996-05-29 | — | — | EP | claimed |
| US-5466858-A | Ruthenium catalyst, high selectivity with a carboxylic acid | UBE INDUSTRIES, LTD. (JP) | 1995-11-14 | — | — | US | claimed |
| US-5332844-A | Method of producing straight-chain acrylonitrile dimers | UBE INDUSTRIES, LTD. (JP) | 1994-07-26 | — | — | US | claimed |
| EP-0559168-A2 | Method of producing straight-chain acrylonitrile dimers | UBE INDUSTRIES, LTD. (JP) | 1993-09-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105952-A1 | Pharmaceutical composition having a ruthenium oxalato compound and method of using the same | OTC, OAT, OSTC | CA4 311/4885FAHD1 849/4885MEN1 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.